Ukr.Biochem.J. 2013; Том 85, № 6, листопад-грудень, c. 18-45

doi: http://dx.doi.org/10.15407/ubj85.06.018

Роль мультидоменної структури урокінази в регуляції росту та ремоделювання судин

15.04.2016   Без категорії   No comments

В. А. Ткачук1,2, О. С. Плеханова1, І. Б. Бєлоглазова1, Є. В. Парфенова1

1ФГБУ Російський кардіологічний науково-виробничий комплекс МОЗ РФ, Москва, Росія;
2Факультет фундаментальної медицини МДУ ім. М. В. Ломоносова, Москва, Росія;
e-mail: plekhanova@mail.ru

Активатор плазміногену урокіназного типу, або урокіназа (uPA) – багато­функціональний протеїн, що грає особливу регуляторну роль у судинній стінці і виявляє здатність запускати протеолітичні та сигнальні каскади. У статті підсумовано одержані авторами результати і дані літератури, що стосуються ролі урокінази в ремоделюванні кровоносних судин і ангіогенезі. Насьогодні урокіназу можна розглядати як перспективну мішень для впливів, спрямованих на профілактику рестенозів, запобігання негативного ремоделювання артерій, стимуляцію росту судин у разі ішемічних захворювань і пригнічення ангіогенезу за онкологічних захворювань.

Ключові слова: , , , ,

Посилання:

  1. Astrup  T, Sterndorff I. An activator of plasminogen in normal urine. Proc Soc Exp Biol Med. 1952 Dec;81(3):675-8. PubMed, CrossRef
  2. Kaulla K. J Lab Clin Med. 1954;44:944-946.
  3. Ploug J, Kjeldgaard NO. Isolation of a plasminogen activator (urokinase) from urine. Arch Biochem Biophys. 1956 Jun;62(2):500-1. PubMed, CrossRef
  4. Schultz RL, von Kaulla KN. The effect of urokinase and fibrinolytic euglobulins on synthetic amino acid esters. Biochem J. 1958 Feb;68(2):218-21. PubMed, PubMedCentral, CrossRef
  5. Parfyonova YV, Plekhanova OS, Tkachuk VA. Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Mosc). 2002 Jan;67(1):119-34. PubMed, CrossRef
  6. Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 1990 Jul;67(1):61-7. PubMed, CrossRef
  7. Tkachuk V, Stepanova V, Little PJ, Bobik A. Regulation and role of urokinase plasminogen activator in vascular remodelling. Clin Exp Pharmacol Physiol. 1996 Sep;23(9):759-65. Review. PubMed, CrossRef
  8. Lijnen HR, Van Hoef B, Nelles L, Collen D. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740—-Ala) and plasmin-resistant scu-PA (Lys158—-Glu). J Biol Chem. 1990 Mar 25;265(9):5232-6. PubMed
  9. Kuzuya M, Iguchi A. Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb. 2003;10(5):275-82. Review. PubMed, CrossRef
  10. Kline TP, Brown FK, Brown SC, Jeffs PW, Kopple KD, Mueller L. Solution structures of human transforming growth factor alpha derived from 1H NMR data. Biochemistry. 1990 Aug 28;29(34):7805-13. PubMed, CrossRef
  11. Mukhina S, Stepanova V, Traktouev D, Poliakov A, Beabealashvilly R, Gursky Y, Minashkin M, Shevelev A, Tkachuk V. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis. J Biol Chem. 2000 Jun 2;275(22):16450-8. PubMed, CrossRef
  12. Stephens RW, Bokman AM, Myöhänen HT, Reisberg T, Tapiovaara H, Pedersen N, Grøndahl-Hansen J, Llinás M, Vaheri A. Heparin binding to the urokinase kringle domain. Biochemistry. 1992 Aug 25;31(33):7572-9. PubMed, CrossRef
  13. Mimuro J, Kaneko M, Murakami T, Matsuda M, Sakata Y. Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1. Biochim Biophys Acta. 1992 Dec 28;1160(3):325-34. PubMed, CrossRef
  14. Kwak SH, Mitra S, Bdeir K, Strassheim D, Park JS, Kim JY, Idell S, Cines D, Abraham E. The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V{beta}3 integrins. J Leukoc Biol. 2005 Oct;78(4):937-45. PubMed, CrossRef
  15. Pluskota E, Soloviev DA, Bdeir K, Cines DB, Plow EF. Integrin alphaMbeta2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem. 2004 Apr 23;279(17):18063-72. PubMed, CrossRef
  16. Bdeir K, Kuo A, Sachais BS, Rux AH, Bdeir Y, Mazar A, Higazi AA, Cines DB. The kringle stabilizes urokinase binding to the urokinase receptor. Blood. 2003 Nov 15;102(10):3600-8. PubMed, CrossRef
  17. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987 Nov 12-18;330(6144):132-7. PubMed, CrossRef
  18. Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G, Blasi F. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem. 1987 Apr 5;262(10):4437-40. PubMed
  19. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985 Jan;100(1):86-92. PubMed, PubMedCentral, CrossRef
  20. Barinka C, Parry G, Callahan J, Shaw DE, Kuo A, Bdeir K, Cines DB, Mazar A, Lubkowski J. Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol. 2006 Oct 20;363(2):482-95. PubMed, PubMed, CrossRef
  21. Magdolen V, Rettenberger P, Koppitz M, Goretzki L, Kessler H, Weidle UH, König B, Graeff H, Schmitt M, Wilhelm O. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur J Biochem. 1996 May 1;237(3):743-51. PubMed, CrossRef
  22. Beloglazova IB, Beabealashvilli RSh, Gursky YG, Bocharov EV, Mineev KS, Parfenova EV, Tkachuk VA. Structural investigations of recombinant urokinase growth factor-like domain. Biochemistry (Mosc). 2013 May;78(5):517-30.  PubMed, CrossRef
  23. Stepanova VV, Beloglazova IB, Gursky YG, Bibilashvily RS, Parfyonova YV, Tkachuk VA. Interaction between kringle and growth-factor-like domains in the urokinase molecule: possible role in stimulation of chemotaxis. Biochemistry (Mosc). 2008 Mar;73(3):252-60. PubMed, CrossRef
  24. Kjaergaard M, Hansen LV, Jacobsen B, Gardsvoll H, Ploug M. Structure and ligand interactions of the urokinase receptor (uPAR). Front Biosci. 2008 May 1;13:5441-61. PubMed, CrossRef
  25. Xu X, Gårdsvoll H, Yuan C, Lin L, Ploug M, Huang M. Crystal structure of the urokinase receptor in a ligand-free form. J Mol Biol. 2012 Mar 9;416(5):629-41. PubMed, CrossRef
  26. Cubellis MV, Nolli ML, Cassani G, Blasi F. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem. 1986 Dec 5;261(34):15819-22.
    PubMed
  27. Poliakov A, Tkachuk V, Ovchinnikova T, Potapenko N, Bagryantsev S, Stepanova V. Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation. Biochem J. 2001 May 1;355(Pt 3):639-45. PubMed, PubMedCentral, CrossRef
  28. Sitrin RG, Pan PM, Harper HA, Todd RF 3rd, Harsh DM, Blackwood RA. Clustering of urokinase receptors (uPAR; CD87) induces proinflammatory signaling in human polymorphonuclear neutrophils. J Immunol. 2000 Sep 15;165(6):3341-9. PubMed, CrossRef
  29. Ghosh S, Brown R, Jones JC, Ellerbroek SM, Stack MS. Urinary-type plasminogen activator (uPA) expression and uPA receptor localization are regulated by alpha 3beta 1 integrin in oral keratinocytes. J Biol Chem. 2000 Aug 4;275(31):23869-76. PubMed, CrossRef
  30. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med. 1998 Sep 21;188(6):1029-37. PubMed, PubMedCentral, CrossRef
  31. Parfenova EV, Plekhanova OS, Men’shikov MIu, Stepanova VV, Tkachuk VA. Regulation of growth and remodeling of blood vessels: the unique role of urokinase. Ross Fiziol Zh Im I M Sechenova. 2009 May;95(5):442-64. Russian. PubMed
  32. Stepanova V, Lebedeva T, Kuo A, Yarovoi S, Tkachuk S, Zaitsev S, Bdeir K, Dumler I, Marks MS, Parfyonova Y, Tkachuk VA, Higazi AA, Cines DB. Nuclear translocation of urokinase-type plasminogen activator. Blood. 2008 Jul 1;112(1):100-10. PubMed, PubMedCentral, CrossRef
  33. Conese M, Nykjaer A, Petersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Christensen EI, Blasi F. alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J Cell Biol. 1995 Dec;131(6 Pt 1):1609-22. PubMed, PubMedCentral, CrossRef
  34. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 1997 May 15;16(10):2610-20. PubMed, PubMedCentral, CrossRef
  35. Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, Nimpf J, Herz J. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem. 2000 Aug 18;275(33):25616-24. PubMed, CrossRef
  36. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist’s view. Thromb Haemost. 2007 Mar;97(3):336-42. Review. PubMed, CrossRef
  37. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996 Apr 1;15(7):1572-82. PubMed, PubMedCentral
  38. Goretzki L, Mueller BM. Low-density-lipoprotein-receptor-related protein (LRP) interacts with a GTP-binding protein. Biochem J. 1998 Dec 1;336(Pt 2):381-6. PubMed, PubMedCentral, CrossRef
  39. Goncharova EA, Vorotnikov AV, Gracheva EO, Wang CL, Panettieri RA Jr, Stepanova VV, Tkachuk VA. Activation of p38 MAP-kinase and caldesmon phosphorylation are essential for urokinase-induced human smooth muscle cell migration. Biol Chem. 2002 Jan;383(1):115-26. PubMed, CrossRef
  40. Tang H, Kerins DM, Hao Q, Inagami T, Vaughan DE. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem. 1998 Jul 17;273(29):18268-72. PubMed, CrossRef
  41. Tarui T, Andronicos N, Czekay RP, Mazar AP, Bdeir K, Parry GC, Kuo A, Loskutoff DJ, Cines DB, Takada Y. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J Biol Chem. 2003 Aug 8;278(32):29863-72. PubMed, CrossRef
  42. Reinartz J, Schäfer B, Batrla R, Klein CE, Kramer MD. Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp Cell Res. 1995 Oct;220(2):274-82. PubMed, CrossRef
  43. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science. 1996 Sep 13;273(5281):1551-5. PubMed, CrossRef
  44. Xue W, Mizukami I, Todd RF 3rd, Petty HR. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 1997 May 1;57(9):1682-9. PubMed
  45. Yebra M, Goretzki L, Pfeifer M, Mueller BM. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res. 1999 Jul 10;250(1):231-40. PubMed, CrossRef
  46. Nguyen DH, Catling AD, Webb DJ, Sankovic M, Walker LA, Somlyo AV, Weber MJ, Gonias SL. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol. 1999 Jul 12;146(1):149-64. PubMed, PubMedCentral, CrossRef
  47. Wei Y, Eble JA, Wang Z, Kreidberg JA, Chapman HA. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell. 2001 Oct;12(10):2975-86. PubMed, PubMedCentral, CrossRef
  48. Zhang F, Tom CC, Kugler MC, Ching TT, Kreidberg JA, Wei Y, Chapman HA. Distinct ligand binding sites in integrin alpha3beta1 regulate matrix adhesion and cell-cell contact. J Cell Biol. 2003 Oct 13;163(1):177-88. PubMed, PubMedCentral, CrossRef
  49. Ragno P. The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol Life Sci. 2006 May;63(9):1028-37. Review. PubMed, CrossRef
  50. Bohuslav J, Horejsí V, Hansmann C, Stöckl J, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med. 1995 Apr 1;181(4):1381-90. PubMed, PubMedCentral, CrossRef
  51. Simon DI, Wei Y, Zhang L, Rao NK, Xu H, Chen Z, Liu Q, Rosenberg S, Chapman HA. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem. 2000 Apr 7;275(14):10228-34. PubMed, CrossRef
  52. Dumler I, Stepanova V, Jerke U, Mayboroda OA, Vogel F, Bouvet P, Tkachuk V, Haller H, Gulba DC. Urokinase-induced mitogenesis is mediated by casein kinase 2 and nucleolin. Curr Biol. 1999 Dec 16-30;9(24):1468-76. PubMed, CrossRef
  53. Behrendt N. The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. Biol Chem. 2004 Feb;385(2):103-36. Review. PubMed, CrossRef
  54. Gårdsvoll H, Gilquin B, Le Du MH, Ménèz A, Jørgensen TJ, Ploug M. Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking. J Biol Chem. 2006 Jul 14;281(28):19260-72. PubMed, CrossRef
  55. Stepanova V, Bobik A, Bibilashvily R, Belogurov A, Rybalkin I, Domogatsky S, Little PJ, Goncharova E, Tkachuk V. Urokinase plasminogen activator induces smooth muscle cell migration: key role of growth factor-like domain. FEBS Lett. 1997 Sep 8;414(2):471-4. PubMed, CrossRef
  56. Poliakov AA, Mukhina SA, Traktouev DO, Bibilashvily RS, Gursky YG, Minashkin MM, Stepanova VV, Tkachuk VA. Chemotactic effect of urokinase plasminogen activator: a major role for mechanisms independent of its proteolytic or growth factor domains. J Recept Signal Transduct Res. 1999 Nov;19(6):939-51. PubMed, CrossRef
  57. Lillis AP, Mikhailenko I, Strickland DK. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J Thromb Haemost. 2005 Aug;3(8):1884-93. Review. PubMed, CrossRef
  58. Kapustin A, Stepanova V, Aniol N, Cines DB, Poliakov A, Yarovoi S, Lebedeva T, Wait R, Ryzhakov G, Parfyonova Y, Gursky Y, Yanagisawa H, Minashkin M, Beabealashvilli R, Vorotnikov A, Bobik A, Tkachuk V. Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration. Biochem J. 2012 Apr 15;443(2):491-503. PubMed, PubMedCentral, CrossRef
  59. Budatha M, Roshanravan S, Zheng Q, Weislander C, Chapman SL, Davis EC, Starcher B, Word RA, Yanagisawa H. Extracellular matrix proteases contribute to progression of pelvic organ prolapse in mice and humans. J Clin Invest. 2011 May;121(5):2048-59. PubMed, PubMedCentral, CrossRef
  60. Wan W, Yanagisawa H, Gleason RL Jr. Biomechanical and microstructural properties of common carotid arteries from fibulin-5 null mice. Ann Biomed Eng. 2010 Dec;38(12):3605-17. PubMed, PubMedCentral, CrossRef
  61. Schluterman MK, Chapman SL, Korpanty G, Ozumi K, Fukai T, Yanagisawa H, Brekken RA. Loss of fibulin-5 binding to beta1 integrins inhibits tumor growth by increasing the level of ROS. Dis Model Mech. 2010 May-Jun;3(5-6):333-42.  PubMed, PubMedCentral, CrossRef
  62. Yanagisawa H, Schluterman MK, Brekken RA. Fibulin-5, an integrin-binding matricellular protein: its function in development and disease. J Cell Commun Signal. 2009 Dec;3(3-4):337-47. PubMed, PubMedCentral, CrossRef
  63. Tarui T, Akakura N, Majumdar M, Andronicos N, Takagi J, Mazar AP, Bdeir K, Kuo A, Yarovoi SV, Cines DB, Takada Y. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost. 2006 Mar;95(3):524-34. PubMed
  64. Carriero MV, Franco P, Votta G, Longanesi-Cattani I, Vento MT, Masucci MT, Mancini A, Caputi M, Iaccarino I, Stoppelli MP. Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors. Curr Drug Targets. 2011 Nov;12(12):1761-71. Review. PubMed, CrossRef
  65. Takada Y. Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis). J Biomed Biotechnol. 2012;2012:136302. PubMed, PubMedCentral, CrossRef
  66. Stephens RW, Pöllänen J, Tapiovaara H, Leung KC, Sim PS, Salonen EM, Rønne E, Behrendt N, Danø K, Vaheri A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol. 1989 May;108(5):1987-95. PubMed, PubMedCentral, CrossRef
  67. Félez J.  Plasminogen binding to cell surfaces. Fibrinolysis Proteolysis. 1998;12(4):183-189. CrossRef
  68. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol. 1997 Oct;9(5):714-24. Review. PubMed, CrossRef
  69. Lijnen HR, Maquoi E, Hansen LB, Van Hoef B, Frederix L, Collen D. Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler Thromb Vasc Biol. 2002 Mar 1;22(3):374-9. PubMed, CrossRef
  70. Menshikov MY, Elizarova EP, Kudryashova E, Timofeyeva AV, Khaspekov Y, Beabealashvilly RS, Bobik A. Plasmin-independent gelatinase B (matrix metalloproteinase-9) release by monocytes under the influence of urokinase. Biochemistry (Mosc). 2001 Sep;66(9):954-9. PubMed, CrossRef
  71. Menshikov M, Elizarova E, Plakida K, Timofeeva A, Khaspekov G, Beabealashvilli R, Bobik A, Tkachuk V. Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem J. 2002 Nov 1;367(Pt 3):833-9. PubMed, PubMedCentral, CrossRef
  72. Menshikov M, Torosyan N, Elizarova E, Plakida K, Vorotnikov A, Parfyonova Y, Stepanova V, Bobik A, Berk B, Tkachuk V. Urokinase induces matrix metalloproteinase-9/gelatinase B expression in THP-1 monocytes via ERK1/2 and cytosolic phospholipase A2 activation and eicosanoid production. J Vasc Res. 2006;43(5):482-90. PubMed, CrossRef
  73. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 1992 Dec;11(13):4825-33. PubMed, PubMedCentral
  74. Plouët J, Moro F, Bertagnolli S, Coldeboeuf N, Mazarguil H, Clamens S, Bayard F. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem. 1997 May 16;272(20):13390-6. PubMed, CrossRef
  75. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol. 1989 Jul;109(1):309-15. PubMed, PubMedCentral, CrossRef
  76. Pendurthi UR, Tran TT, Post M, Rao LV. Proteolysis of CCN1 by plasmin: functional implications. Cancer Res. 2005 Nov 1;65(21):9705-11. PubMed, PubMedCentral, CrossRef
  77. Odekon LE, Sato Y, Rifkin DB. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol. 1992 Feb;150(2):258-63. PubMed, CrossRef
  78. Okada SS, Grobmyer SR, Barnathan ES. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. Arterioscler Thromb Vasc Biol. 1996 Oct;16(10):1269-76. PubMed, CrossRef
  79. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol. 1994 Jul;126(1):259-70. PubMed, PubMedCentral, CrossRef
  80. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA. 2002 Feb 5;99(3):1359-64. PubMed, PubMedCentral, CrossRef
  81. Kiyan J, Kiyan R, Haller H, Dumler I. Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-beta. EMBO J. 2005 May 18;24(10):1787-97.  PubMed, PubMedCentral, CrossRef
  82. Jo M, Thomas KS, O’Donnell DM, Gonias SL. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem. 2003 Jan 17;278(3):1642-6.  PubMed, CrossRef
  83. Roztocil E, Nicholl SM, Davies MG. Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration. J Surg Res. 2007 Jul;141(1):83-90.
    PubMed, PubMedCentral, CrossRef
  84. Ossowski L, Aguirre Ghiso J, Liu D, Yu W, Kovalski K. The role of plasminogen activator receptor in cancer invasion and dormancy. Medicina (B Aires). 1999;59(5 Pt 2):547-52. PubMed
  85. Dumler I, Weis A, Mayboroda OA, Maasch C, Jerke U, Haller H, Gulba DC. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem. 1998 Jan 2;273(1):315-21. PubMed, CrossRef
  86. Koshelnick Y, Ehart M, Hufnagl P, Heinrich PC, Binder BR. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J Biol Chem. 1997 Nov 7;272(45):28563-7. PubMed, CrossRef
  87. Frame MC, Fincham VJ, Carragher NO, Wyke JA. v-Src’s hold over actin and cell adhesions. Nat Rev Mol Cell Biol. 2002 Apr;3(4):233-45. Review. PubMed, CrossRef
  88. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene. 2000 Nov 20;19(49):5606-13. Review. PubMed, CrossRef
  89. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, Parsons JT. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene. 2001 Mar 8;20(10):1152-63. PubMed, CrossRef
  90. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997 Dec 15;16(24):7279-86. PubMed, PubMedCentral, CrossRef
  91. Kjøller L, Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol. 2001 Mar 19;152(6):1145-57. PubMed, PubMedCentral, CrossRef
  92. Willnow TE, Nykjaer A, Herz J. Lipoprotein receptors: new roles for ancient proteins. Nat Cell Biol. 1999 Oct;1(6):E157-62. Review. PubMed, CrossRef
  93. Ma Z, Thomas KS, Webb DJ, Moravec R, Salicioni AM, Mars WM, Gonias SL. Regulation of Rac1 activation by the low density lipoprotein receptor-related protein. J Cell Biol. 2002 Dec 23;159(6):1061-70. PubMed, PubMedCentral, CrossRef
  94. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noël A. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol. 2001 Feb 19;152(4):777-84. PubMed, PubMedCentral, CrossRef
  95. Alexander RA, Prager GW, Mihaly-Bison J, Uhrin P, Sunzenauer S, Binder BR, Schütz GJ, Freissmuth M, Breuss JM. VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution. Cardiovasc Res. 2012 Apr 1;94(1):125-35. PubMed, CrossRef
  96. Kirchheimer JC, Wojta J, Christ G, Binder BR. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci USA. 1989 Jul;86(14):5424-8. PubMed, PubMedCentral, CrossRef
  97. Kirchheimer JC, Wojta J, Christ G, Hienert G, Binder BR. Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells. Carcinogenesis. 1988 Nov;9(11):2121-3. PubMed, CrossRef
  98. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 2001 Apr;12(4):863-79. PubMed, PubMedCentral, CrossRef
  99. Gyetko MR, Sud S, Chen GH, Fuller JA, Chensue SW, Toews GB. Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection. J Immunol. 2002 Jan 15;168(2):801-9. PubMed, CrossRef
  100. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J, Goltzman D. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun. 1990 Dec 31;173(3):1058-64. PubMed, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.